Short-course Radiotherapy Combined With CAPOX and PD-1 Antibody Versus Long-course Chemoradiotherapy Combined With CAPOX for Early Low-lying Rectal Cancer

Short-course Radiotherapy Combined With CAPOX and PD-1 Antibody Versus Long-course Chemoradiotherapy Combined With CAPOX for Early Low-lying Rectal Cancer is a phase 2, randomised interventional study registered as NCT06462053 by Fudan University, with a registry enrolment figure of 134 participants, started 2024-04-01 and due to reach its primary completion in 2026-04-01. Interventions recorded: Short-course radiotherapy; PD-1 antibody (Toripalimab); Long-course radiotherapy; Oxaliplatin; Capecitabine. Conditions listed: Early Low Rectal Cancer. Primary outcome: complete response (CR) rate. Sites: China. No results are recorded here; the registry entry is the source.